key: cord-0766985-spiun6w2
authors: Yang, Yi; Shi, Jia; Ge, Shuwang; Guo, Shuiming; Xing, Xue; Wang, Yanan; Cheng, Anying; Liu, Qingquan; Li, Junhua; Ning, Yong; He, Fan; Xu, Gang
title: Association between Prolonged Intermittent Renal Replacement Therapy and All-Cause Mortality in COVID-19 Patients Undergoing Invasive Mechanical Ventilation: A Retrospective Cohort Study
date: 2020-12-03
journal: Blood Purif
DOI: 10.1159/000512099
sha: 1a54f847162ce5d3cbbc48639ccbfba38e399bc1
doc_id: 766985
cord_uid: spiun6w2

BACKGROUND: The mortality rate of critically ill patients with coronavirus disease 2019 (COVID-19) was high. We aimed to assess the association between prolonged intermittent renal replacement therapy (PIRRT) and mortality in patients with COVID-19 undergoing invasive mechanical ventilation. METHODS: This retrospective cohort study included all COVID-19 patients receiving invasive mechanical ventilation between February 12 and March 2, 2020. All patients were followed until death or March 28, and all survivors were followed for at least 30 days. RESULTS: For 36 hospitalized COVID-19 patients receiving invasive mechanical ventilation, the mean age was 69.4 (±10.8) years, and 30 patients (83.3%) were men. Twenty-two (61.1%) patients received PIRRT (PIRRT group), and 14 cases (38.9%) were managed with conventional strategy (non-PIRRT group). There were no differences in age, sex, comorbidities, complications, treatments, and most of the laboratory findings. During the median follow-up period of 9.5 (interquartile range 4.3–33.5) days, 13 of 22 (59.1%) patients in the PIRRT group and 11 of 14 (78.6%) patients in the non-PIRRT group died. Kaplan-Meier analysis demonstrated prolonged survival in patients in the PIRRT group compared with that in the non-PIRRT group (p = 0.042). The association between PIRRT and a reduced risk of mortality remained significant in 3 different models, with adjusted hazard ratios varying from 0.332 to 0.398. Increased IL–2 receptor, TNF-α, procalcitonin, prothrombin time, and NT-proBNP levels were significantly associated with an increased risk of mortality in patients with PIRRT. CONCLUSION: PIRRT may be beneficial for the treatment of COVID-19 patients with invasive mechanical ventilation. Further prospective multicenter studies with larger sample sizes are required.

Coronavirus disease 2019 (COVID- 19) is an epidemic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] . In Wuhan, the fatality rate of COVID-19 was 5.1% (2,538/50,006) . Of note, critically ill patients with COVID-19 have a much higher mortality rate. In a study of 52 critically ill patients in Wuhan, 32 (61.5%) patients had died after 28 days, and the mortality rate was 81.1% (30/37) in patients requiring mechanical ventilation [2] . Accumulated evidence has strongly demonstrated that systemic inflammatory response, acute kidney injury (AKI), and fluid overload were associated with high mortality in severe sepsis [3] [4] [5] . In critically ill patients with COVID-19, an overwhelming inflammatory response involving C-reactive protein, interleukin (IL)-6, IL-8, IL-10, and tumor necrosis factor α (TNF-α) was observed [6] [7] [8] [9] , which is similar to that observed in patients suffering from SARS-CoV [10] and Middle East respiratory syndrome (MERS)-CoV [11] .

Renal replacement therapy (RRT) is of great help in the treatment of critically ill patients, not only controlling electrolyte and acid-base imbalance but also clearing inflammatory mediators and improving oxygenation in the case of fluid overload [12] [13] [14] . RRT has been applied to critically ill patients, including SARS-CoV, MERS-CoV, and other viral infectious diseases such as Ebola virus disease [13, 15] . There is still no consensus on the benefits of RRT in critically ill patients [16] . RRT can significantly reduce IL-6 level and hospital mortality in children with severe sepsis, especially acute respiratory distress syndrome [17] . In addition, a meta-analysis showed a significant reduction in mortality in patients receiving RRT compared with conventional treatment [18] . However, RRT was associated with increased mortality in MERS-CoV patients [15] . The relationship between RRT and patient prognosis varied among patients with different diseases and was influenced by RRT modalities, anticoagulant use, vascular access management, start-up time, and intensity [16, 19, 20] .

Prolonged intermittent renal replacement therapy (PIRRT), as a cost-effective alternative, has been used in the intensive care unit [21, 22] . To date, no specific treatment has been proven effective for COVID-19, and supportive care remains critical. In this retrospective cohort study, we aimed to investigate the association between PIRRT and all-cause mortality in patients with COV-ID-19 undergoing invasive mechanical ventilation. This retrospective cohort study included COVID-19 patients  undergoing invasive mechanical ventilation at the Optical Valley  Branch of Tongji Hospital, Wuhan, from February 12 to March 2. The subjects were divided into 2 groups (PIRRT group and non-PIRRT group) according to the use of PIRRT treatment.

All included patients met the COVID-19 diagnostic criteria of the New Coronavirus Pneumonia Prevention and Control Program (Fifth Edition, in Chinese) published by the National Health Commission of China [23] . Invasive mechanical ventilation was defined as mechanical ventilation through an endotracheal tube or tracheostomy. There were no exclusion criteria.

Baseline data were collected and recorded for each patient at the start of invasive mechanical ventilation, including age, sex, comorbidities, complications, laboratory data, and treatments. All information was obtained and managed through established data collection forms. Two researchers independently reviewed and collected the data.

We performed PIRRT using commercially available pumpdriven machines (PrismaFlex, Gambro, Sweden; or multiFiltrate, Fresenius, Germany) and appropriate circuit set with filter (M150 set, Gambro; Oxiris set, Baxter; or multiFiltrate cassette with AV1000s, Fresenius). For the patients with AKI, hemofiltration plus hemodialysis was performed. The blood flow rate, the ultrafiltration rate, and the clearance rate were set at 2.5-4 mL/kg/min, 0-5 mL/kg/h, and 35-70 mL/kg/h, respectively. Central venous catheterization circuit was obtained with a 24-cm long 13.5-F central venous catheter (Covidien, MA, USA) in the femoral vein. The filter circuit was prewashed with saline containing 5,000-6,250 IU/L heparin. PIRRT modalities were venovenous hemodiafiltration in 22.7% (5/22) of the patients and venovenous hemofiltration in 77.3% (17/22) of the patients. Patients received 8 h of PIRRT once a day or every other day.

The indications for PIRRT were as follows: (1) nonobstructive oliguria (urine output <200 mL/12 h) or anuria or AKI stage 3 (serum Cr increase ≥3 times baseline with 7 days); (2) hyperkalemia (K+ >6.5 mmol/L); (3) acidemia (PH <7.1); (4) clinically significant organ edema (especially pulmonary edema); (5) uremic complications (pericarditis/encephalopathy/neuropathy/myopathy); (6) azotemia (urea >30 mmol/L); (7) (optional) increased inflammatory cytokines (anyone of IL-1β, IL-2 receptor, IL-6, IL-8, or TNF-α ≥5 times of upper limit of normal range).

All patients were followed through hospital electronic medical records. The primary outcome was death, with all patients followed up to death or March 28, and all survivors followed up for at least 30 days. There was no loss to follow-up for patients.

Numerical data were presented as the mean and SD or median (interquartile range [IQR]) and analyzed using Student's t test or PIRRT in COVID-19 Patients the Mann-Whitney U test according to data distribution. Categorical variables were displayed as frequencies and percentages and analyzed using Fisher's exact test. Paired t test or Wilcoxon matched-pairs signed rank test were used to evaluate the differences of variables between before and after PIRRT. The Kaplan-Meier method was used to estimate survival, and the log-rank test was used to evaluate differences between the 2 groups. Univariate and multivariate Cox proportional hazards regression analyses were performed for all-cause mortality. SPSS 23.0 (IBM Corporation, Armonk, NY, USA) statistical software and GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA) were used for statistical analysis and visualization. A p value of 0.05 or less was considered significant.

In total, 36 COVID-19 patients subjected to invasive mechanical ventilation were enrolled in the study. Table 1 shows the baseline characteristics of the cohort patients. There were 30 men (83.3%) and 6 women (16.7%) ranging in age from 44 to 86 years. Thirty patients (83.3%) had at least 1 comorbidity, and the common comorbidity factors in COVID-19 patients with invasive mechanical ven-tilation were hypertension (n = 14, 38.9%) and cardiac disease (n = 12, 33.3%).

We divided the subjects into 2 groups based on PIRRT. Twenty-two patients received PIRRT (PIRRT group) while 14 patients did not (non-PIRRT group). There was no difference between the 2 groups in baseline characteristics including age, sex, acute physiology, and chronic health evaluation (APACHE) II scores, sepsis-related organ failure assessment (SOFA) scores, comorbidities, complications, treatments, or most laboratory findings, except for patients who received PIRRT with higher levels of aspartate aminotransferase (p = 0.034) and serum Cr (p = 0.017).

The indications for PIRRT (n = 22) were as follows: (1) AKI at stage 3 with or without hyperkalemia or pulmonary edema: n = 4; (2) hyperkalemia: n = 1; (3) acidemia: n = 1; (4) pulmonary edema: n = 1; (5) (optional) increased inflammatory cytokines (anyone of IL-1β, IL-2, IL-6, IL-8 receptors or TNF-α ≥5 times of upper limit of normal range): n = 15. There was no definite indication of PIRRT for patients in the non-PIRRT group. Our evaluation of dialysis indications was consistent in all patients, except for inflammatory cytokines. Furthermore, 

All survivors were followed for at least 30 days. During the median follow-up period of 9.5 (IQR 4.3-33.5) days, 13 of 22 (59.1%) patients in the PIRRT group and 11 of 14 (78.6%) patients in the non-PIRRT group died. Kaplan-Meier analysis indicated that the survival time of patients in the PIRRT group was prolonged compared with the non-PIRRT group (p = 0.04) (shown in Fig. 1) .

Three different models were used in the Cox regression analysis to analyze the adjusted hazard ratio for PIRRT treatment. Consistently, the association between PIRRT treatment and reduced risk of mortality remained significant, while the adjusted hazard ratio for PIRRT treatment fluctuated between 0.332 and 0.398 (Table 2) . Univariate Cox proportional hazard regression analysis showed that increased IL-6 (HR = 1.004, 95% CI [1.001-1.007]) and TNF-α (HR = 1.040, 95% CI [1.007-1.073]) were associated with increased risk of mortality of all patients with invasive mechanical ventilation.

We further conducted a univariate Cox proportional hazard regression analysis of all-cause mortality in CO-VID-19 patients undergoing invasive mechanical ventilation with PIRRT. We found that increased IL-2 receptor, TNF-α, procalcitonin, prothrombin time, and NT-pro-BNP levels were significantly associated with an increased risk of all-cause mortality (Table 3 ).

To our knowledge, this study is the first cohort to estimate the association between PIRRT treatment and mortality in COVID-19 patients receiving invasive mechanical ventilation. Invasive mechanical ventilation was performed on 36 COVID-19 patients, of whom 22 received PIRRT. During follow-up, 59.1% of the patients in the PIRRT group and 78.6% in the non-PIRRT group died. PIRRT was independently associated with prolonged survival and reduced risk of mortality in COVID-19 patients requiring invasive mechanical ventilation. The research has been published on medRxiv [24] .

Excessive inflammation previously characterized by uncontrolled release of pro-inflammatory cytokines into circulation is the leading cause of death in patients with sepsis [25, 26] and viral infectious diseases, such as influenza virus [27] , Ebola virus [28] , MERS-CoV [29] , and SARS-CoV [30] . In our study, we found that the cytokine storm might Model A, adjusted for APACHE II scores, SOFA scores, and any of comorbidity; Model B, adjusted for acute kidney injury, APACHE II scores, sex; Model C, adjusted for IL-6, APACHE II scores, IL-2 receptor. COVID-19, coronavirus disease 2019; PIRRT, prolonged intermittent renal replacement therapy; APACHE II, acute physiology and chronic health evaluation II; SOFA, sepsis-related organ failure assessment. play a crucial role in severe cases of COVID-19. The mean/ median levels of inflammatory markers, including IL-1β, IL-2 receptor, IL-6, IL-8, and IL-10, white blood cell count, neutrophil count, hCRP, procalcitonin, and ferritin were higher than normal. In our study, univariate Cox proportional hazard regression analysis showed that increased IL-6 and TNF-α were both associated with increased risk of mortality in all patients with invasive mechanical ventilation. Besides, in patients receiving PIRRT, a significant difference of IL-6 before and after PIRRT was observed: before versus after PIRRT: 221. 35 Cytokine storms may be caused by several factors. First, SARS-CoV-2 infects patients by binding to human angiotensin (Ang)-converting enzyme 2 (ACE2) [31, 32] , which is widely expressed in multiple organs throughout the body [33] . SARS-CoV-2 might lead to multisystem inflammation through the ACE/Ang II/AT1R pathway and the ACE2/Ang [1] [2] [3] [4] [5] [6] [7] /Mas receptor pathway [34, 35] . Second, it has been reported that antibody-dependent enhancement of SARS-CoV-2 due to previous exposure to other coronaviruses may also be associated with COVID-19 [36] .

Third, coinfection may lead to a more severe systemic inflammatory response. Indeed, in our study, some patients were infected with other pathogens (e.g., influenza virus and fungi) in other organs (such as urinary tract and blood). Last, shock, hypoxemia, and abnormal coagulation pathways in critically ill patients can aggravate systemic inflammatory response, forming a life-threatening vicious cycle [37, 38] .

In our study, PIRRT was associated with prolonged survival in COVID-19 patients on invasive mechanical ventilation. The primary goal of RRT is to compensate for the loss of renal function and associated sequelae, including uremic toxicity, electrolyte disturbances, metabolic acidosis, and volume overload [22, 39] . In addition, RRT can also clear cytokines from the blood. Emerging evidences have shown that RRT is associated with significantly reduced mortality in patients with severe sepsis [17, 18, 40] . Besides, in patients with acute respiratory distress syndrome, RRT could clear inflammatory mediators, regulate immune function, and regulate oxygenation, thereby improving patient prognosis [41] [42] [43] . PIRRT is a widely used blood purification therapy that achieves a high solute clear- ance rate through diffusion and convection [44] . In intensive care units, PIRRT has been shown to encompass the benefits of both continuous RRT in terms of hemodynamic stability and intermittent hemodialysis in terms of costefficiency [22, 45] . In practical clinical work, PIRRT may be more flexible, realistic, and timely in the face of a large number of critically ill COVID-19 patients with different demands for treatment.

However, the available data on whether PIRRT is beneficial for viral pneumonia appears somewhat contradictory. RRT has been reported to have a positive effect on the treatment of adenovirus pneumonia [46] . Other studies have shown that PIRRT is a risk factor for mortality in MERS-CoV patients [15, 47] . Yang et al. [48] also found a higher percentage of non-survivors receiving RRT in CO-VID-19 patients. In our study, PIRRT was associated with a reduced risk of mortality in COVID-19 patients requiring invasive mechanical ventilation after adjusting for confounders. COVID-19 is a novel infectious disease caused by a novel coronavirus, and the pathophysiological process related to organ involvement is still unclear. In addition, the population in our cohort study was different from that of Yang et al. [48] , which focused on all critically ill patients, while we focused on patients receiving invasive mechanical ventilation. Further research is needed to improve patient care and prognosis.

There were some limitations to our study. First, the design is retrospective, and prospective double-blind randomized controlled studies are warranted in the future. Second, the sample size of this study is not large enough. Third, because it is a single-center study, it needs to be confirmed by multicenter study. Last, the variety of PIRRT prescriptions leads to the lack of consistency in treatment. More uniform prospective studies are needed.

In summary, we demonstrate that PIRRT can improve the survival of COVID-19 patients and may be an independent protective factor for COVID-19 patients undergoing invasive mechanical ventilation. Prospective multicenter studies with larger sample sizes are also needed.

A novel coronavirus from patients with pneumonia in China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies

Fluid management in the critically ill

The epidemiology of sepsis in Chinese ICUs: a national cross-sectional survey

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Clinical predictors of mortality due to COV-ID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med

Clinical characteristics of coronavirus disease 2019 in China

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

MERS-CoV infection in humans is associated with a proinflammatory Th1 and Th17 cytokine profile

IDEAL timing of renal replacement therapy in critical care

Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care

Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review

Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: a cohort study

Prescription of CRRT: a pathway to optimize therapy

Continuous renal replacement therapy in pediatric severe sepsis: a propensity score-matched prospective multicenter cohort study in the PICU

Blood purification with continuous veno-venous hemofiltration in patients with sepsis or ARDS: a systematic review and meta-analysis

Timing of renal replacement therapy initiation for acute kidney injury

Intensity of continuous renal replacement therapy for acute kidney injury

Accelerated venovenous hemofiltration as a transitional renal replacement therapy in the intensive care unit

Pediatric Continuous Renal Replacement Therapy (PCRRT) expert committee recommendation on prescribing prolonged intermittent renal replacement therapy (PIRRT) in critically ill children

The new coronavirus pneumonia prevention and control program

Association between prolonged intermittent renal replacement therapy and allcause mortality in COVID-19 patients undergoing invasive mechanical ventilation: a retrospective cohort study. medRxiv

Cytokine storm and sepsis disease pathogenesis

Failure of treatments based on the cytokine storm theory of sepsis: time for a novel approach

Ponatinib protects mice from lethal influenza infection by suppressing cytokine storm

Phosphatidylserine's role in Ebola's inflammatory cytokine storm and hemorrhagic consumptive coagulopathy and the therapeutic potential of annexin V. Med Hypotheses

Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment

Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response

COVID-19 (novel coronavirus 2019): recent trends

SARS-CoV-2 cell entry depends on ACE2 and TM-PRSS2 and is blocked by a clinically proven protease inhibitor

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)

Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect

Sepsis, oxidative stress, and hypoxia: are there clues to better treatment?

Systemic inflammatory response syndrome

Clinical review: timing of renal replacement therapy

Efficacy of continuous hemodiafiltration with a cytokine-adsorbing hemofilter in the treatment of acute respiratory distress syndrome

Impact of continuous renal replacement therapy on oxygenation in children with acute lung injury after allogeneic hematopoietic stem cell transplantation

Early initiation of continuous renal replacement therapy improves clinical outcomes in patients with acute respiratory distress syndrome

Continuous veno-venous hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation or chemotherapy

Prolonged intermittent renal replacement therapy

Single-best choice between intermittent versus continuous renal replacement therapy: a review

Severe ARDS caused by adenovirus: early initiation of ECMO plus continuous renal replacement therapy

Renal complications and their prognosis in Korean patients with middle east respiratory syndrome-coronavirus from the central MERS-CoV designated hospital

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

The authors greatly appreciate all the hospital staff for their efforts in recruiting and treating patients and thank all patients involved in this study.

The study protocol and waiver of written informed consent were approved by the Medical Ethics Committee of Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology (No. TJ-C20200333).

The authors declare that they have no competing interests.

This study was funded by the National Natural Science Foundation of China (NSFC 81974089), international (regional) coop-